215380 — Woojung BIO Income Statement
0.000.00%
Last trade - 00:00
- KR₩22bn
- KR₩77bn
- KR₩39bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 32,290 | 37,344 | 31,238 | 46,918 | 38,616 |
Cost of Revenue | |||||
Gross Profit | 9,788 | 5,299 | 5,877 | 6,727 | 6,290 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 31,648 | 42,649 | 34,764 | 50,286 | 44,882 |
Operating Profit | 642 | -5,305 | -3,526 | -3,368 | -6,266 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 14.4 | -10,568 | -1,926 | -1,866 | -5,054 |
Provision for Income Taxes | |||||
Net Income After Taxes | 280 | -10,879 | -1,926 | -1,880 | -5,054 |
Net Income Before Extraordinary Items | |||||
Net Income | 280 | -10,879 | -1,926 | -1,880 | -5,054 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 280 | -10,879 | -1,926 | -1,880 | -5,054 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 9.19 | -939 | -156 | -99.8 | -256 |
Dividends per Share |